Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lersivirine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | PGR | P06401 | 8/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lersivirine SCHEMBL509058 | 0.94 | KCNH2 (0.45) | KCNH2PGRCYP11B2ALDH1A1LMNA | |
| SCHEMBL508393 | 0.94 | KCNH2 (0.44) | KCNH2PGRCYP11B2ALDH1A1LMNA | |
| Lersivirine SCHEMBL508803 | 0.93 | KCNH2 (0.44) | KCNH2PGRPTGDR2 | |
| SCHEMBL2717137 | 0.93 | KCNH2 (0.53) | KCNH2PGRCYP11B2ALDH1A1LMNA | |
| SCHEMBL508232 | 0.93 | KCNH2 (0.47) | KCNH2PGRCYP11B2PTGDR2 | |
| SCHEMBL2716684 | 0.92 | KCNH2 (0.54) | KCNH2PGRPTGDR2CYP3A4 | |
| SCHEMBL2717095 | 0.92 | KCNH2 (0.42) | KCNH2PGRCYP3A4 | |
| SCHEMBL509331 | 0.91 | KCNH2 (0.41) | KCNH2PGR | |
| SCHEMBL1347126 | 0.90 | KCNH2 (0.51) | KCNH2PGRCYP11B2PTGDR2 | |
| SCHEMBL509057 | 0.89 | PGR (0.41) | KCNH2PGRALDH1A1LMNAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025151774-A1 | TREATING INFLAMMATORY RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | claimed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | claimed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | claimed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | claimed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | claimed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | KCNH2 3441/4885PGR 641/4885CYP11B2 916/4885 |
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | KCNH2 4380/4885PGR 3329/4885CYP11B2 32/4885 |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | IRF3, STING1, MAVS | KCNH2 4758/4885PGR 3897/4885CYP11B2 1676/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | KCNH2 3304/4885PGR 893/4885CYP11B2 960/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | KCNH2 2690/4885PGR 2580/4885CYP11B2 19/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885PGR 1045/4885CYP11B2 415/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | KCNH2 4748/4885PGR 537/4885CYP11B2 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.